Thrombosis Profile ELISA

产品名称：Thrombosis Profile ELISA
产    地：Demeditec 
产品货号：DE7600
产品规格：96 Tests
产品说明：
Special remarks:
The Thrombosis Profile assay is a quantitative enzyme immunoassay (EIA) intended to screen for the presence of IgG and IgM class autoantibodies against b2-Glycoprotein I, Cardiolipin,  Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic acid in human serum or plasma as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders.
The first study of antiphospholipid antibodies began in 1906, when Wasserman intro-duced a serological test for Syphilis. In 1942, the active component was found to be a phospholipid, which was designated Cardiolipin. In the 1950s it became clear that a number of people had positive tests for syphilis without any evidence of the disease. This phenomenon was refer-red to as the biological false positive serological test for syphilis. A high prevalence of autoimmune disorders, including systemic lupus erythematosus (SLE) and Sjögrens Syndrome occurred in this group of patients.
The presence of circulating anti-coagulants in patients with SLE was first documented in 1952 and was associated with increased risk of paradoxical Thrombosis in 1963. The term Lupus anticoagulant (LA) was first used in 1972, is clearly a misnomer, because LA is more frequently encountered in patients without lupus and is associated with thrombosis rather than abnormal bleeding.
During the last years it became clear that the optimal binding of anti phospholipid antibodies is de-pending on a co-factor termed b2-Glycoprotein I (apolipoprotein H) (GPI). GPI is a 50 kDa b2-globulin occurring in plasma at a level of 200 µg/ml. It has been found that b2-Glycoprotein I (b2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. ß2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipo-proteins. The phospholipid binding region is located on its fifth domain.
Under the acronym "aPL" (anti-Phospholipid antibodies) antibodies against negatively charged phospholipids, such as CL (Cardiolipin), LA (Lupus Anticoagulant), PS (Phosphatidylserine), PI (Phosphatidylinositol) and PA (Phosphatidic Acid) are summarised. Of these, CL is the phospholipid most commonly used as antigen to test for aPL by ELISA. Some antisera which bind cardiolipincoated ELISA plates can also bind plates coated with other negatively charged phospholipids, such as phosphatidylserine (PS) and phosphatidic acid (PA).
Some investigators have suggested that the use of PS in place of cardiolipin in ELISA tests enables more specific diagnosis. These antigens are less commonly used and their additional use can improve the clinical sensitivity in patient samples with sus-pected APS (Anti-Phospholipid-Syn-drome), but at this time it seems that they can't replace the measurement of autoantibodies against Cardiolipin. To find out more about the different clinical relevance of the different phospholipid autoantibodies, we designed the Thrombosis Profile test system.
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位，公司提供的产品涵盖了二十多个国家近五十万种产品，而且产品的数量与信息在不断的增长和更新，公司提供的产品能够使生命科学工作者加快对生物化学，分子生物学，细胞生物学以及蛋白质组学研究的认知，以及分子诊断和临床医学领域的应用。

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!